Jain V, et al. - By performing this study on patients with stage I–IV melanoma diagnosed from 2011 to 2015, researchers determined how the stage at diagnosis, receipt of immunotherapy, and overall survival in these patients were influenced by insurance. In this study, the National Cancer Database was used. There were 167,130 patients in total, with 52% having commercial insurance, 43% having Medicare, 3% having Medicaid and 2% were uninsured. Among patients below 65 years, a higher probability of presenting with metastatic melanoma and less chance to receive immunotherapy was observed in those with Medicaid and the uninsured vs those with commercial insurance. An inferior overall survival (OS) was observed in patients with Medicaid and no insurance among those treated with immunotherapy. In patients 65 years or above, an increased probability of presenting with metastatic disease was reported in relation to Medicare but no significant difference in receipt of immunotherapy or OS was revealed vs commercial insurance. Findings revealed the link of insurance with the stage at diagnosis, receipt of immunotherapy, and OS in patients below 65 years old with melanoma.